----item----
version: 1
id: {65554820-C16E-4C5C-BF8F-B9AB17F603CC}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/11/11/Cellectis Success With OffTheShelf CART Threatens Kite Juno Novartis
parent: {5EDD049F-1031-4290-8719-6CA0186009DA}
name: Cellectis Success With OffTheShelf CART Threatens Kite Juno Novartis
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 7469b487-c6a2-4340-a24c-8532904d451d

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 76

 Cellectis Success With Off-The-Shelf CAR-T Threatens Kite, Juno, Novartis  
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 68

Cellectis Success With OffTheShelf CART Threatens Kite Juno Novartis
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 14047

<p> <b>An unexpected breakthrough announced by Cellectis for its experimental off-the-shelf CAR-T therapy has raised the possibility that much-hyped therapies using a patient's own cells, under development at Kite, Juno and Novartis, may become commercially obsolete before they even reach the market.</b> </p> <p> Cellectis announced on Nov. 5, 2015 that an 11-month-old baby girl was put into remission using UCART19, its off-the-shelf experimental CAR-T therapy. While these preliminary results are based on a limited single-patient application, UCART19's universal administration could pose a significant threat to CAR-Ts being developed by Kite, Juno, and Novartis, as their personalized therapies have high costs of production and logistical challenges likely to limit market access. </p> <p> In this case, the child, who suffered from progressive acute lymphoblastic leukemia (ALL), had exhausted all other treatment options. Unable to generate personalized CAR-T cells from the patient, doctors administered the off-the-shelf UCART19 under an emergency compassionate-use protocol. Two months after treatment with the experimental therapy, the child has apparently been cleared of cancer. </p> <p> If Cellectis' approach is more widely validated, there could be significant fall-out for companies that are developing ways of using a patient's own cells to create CAR-T immunotherapies. This is because of the difference in the complexity and cost of the autologous (ie personalized) approach compared with the allogeneic (ie. off the shelf, donor cell-based) approach. </p> <p> <img border="0" src="-/media/D76048631176490FB480A26E8C60389E.ashx"> </p> <p> Despite the impressive clinical efficacy for autologous CAR-T therapies highlighted by trials thus far, their administration will likely be limited to specialized transplantation centers immediately post-approval, where physicians and scientists will be able to extract T-lymphocytes from patients for transformation and reinfusion. In addition, current production processes require between one to two weeks in order to genetically engineer the patient's T-cells to express the appropriate chimeric antigen receptor (CAR). The large investments in time and resources required for production will certainly translate to higher prices for patients. As a result, the major challenge for manufacturers of autologous CAR-T therapies will be the shift to large scale production because of the costs associated with such personalized therapies. This could significantly impact wide-scale distribution and severely limit commercial uptake. </p> <p> Cellectis' off-the-shelf therapies, by contrast, will use T-lymphocytes derived from healthy third-party donors, and will be manufactured to scale using contract manufacturing organizations. In theory, allogeneic CAR-T approaches could supply thousands of treatments from a single T-lymphocyte since healthy donor cells can be grown into larger populations following isolation. Such development platforms also allow for streamlined production, quality control, and ease of distribution. This would result in a significantly lower cost. The CAR-Ts would then be frozen after manufacturing, and shipped anywhere in the world for immediate use. This off-the-shelf approach could lead to a faster, more affordable product, potentially rendering autologous technologies obsolete. </p> <p> Up until now autologous CAR-Ts have long been considered the more promising of the two approaches since therapies derived from a patient's own cells may be less likely to be rejected. However, UCART19 circumvents this by knocking out the T-cell receptor (TCR), which mediates immune responses following allogeneic transplant. Success for Cellectis could tip the balance. </p> <p> Kite Pharma, Inc., Juno Therapeutics, Inc., and Novartis AG are all currently seeking ways to expedite the manufacture of their respective CAR-T technologies in anticipation of their approval. All three companies have received breakthrough therapy designation from the United States Food and Drug Administration (FDA) for their lead autologous CAR-T candidates, and they are expected to begin seeking regulatory approval for advanced hematological malignancies in 2016. </p> <p> In September 2014, Novartis and the University of Pennsylvania announced plans for the construction of a research and development facility on the university campus dedicated to CAR research. Kite has also announced the establishment of two manufacturing facilities in Southern California, while Juno is leasing its own facility in Washington. </p> <p> Initial market penetration is likely to be low, however, due to the limited scale of production. And if the impressive single-patient data of UCART19 is reflected in larger-scale studies, manufacturers of autologous therapies would need to think seriously about how their therapies could compete. </p> <p> The outlook for the wider CAR-T field now depends on whether Cellectis can repeat its breakthrough results on a larger scale, where efficacy and toxicity concerns can be better characterized. In addition, these preliminary data (to be reported at the <a target="_new" href="https://ash.confex.com/ash/2015/webprogram/Paper81653.html">57th American Society of Hematology Annual Meeting</a> in December) report cancer clearance just two months after the child's treatment, but longer observation will be necessary to know whether the remission is durable. It is still too early to determine UCART19's impact on the CAR-T market, as major manufacturers have yet to seek even regulatory approval. However, if Cellectis' proof-of-concept leads to effective, affordable therapies for cancer, future manufacturers will surely follow in the development of off-the-shelf CAR-T therapies to reap the commercial reward. </p> <p><p> <table> <h2> Table: Major allogeneic and autologous CAR-T development candidates </h2> <tr> <td> <p> Lead Company </p> <p> &nbsp; </p> </td> <td> <p> Technology Name </p> <p> &nbsp; </p> </td> <td> <p> Autologous/Allogeneic </p> <p> &nbsp; </p> </td> <td> <p> Indication </p> <p> &nbsp; </p> </td> <td> <p> Phase </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Novartis </p> <p> &nbsp; </p> </td> <td> <p> CTL019 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Chronic lymphocytic leukemia/small cell lymphocytic lymphoma </p> <p> &nbsp; </p> </td> <td> <p> II </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Novartis </p> <p> &nbsp; </p> </td> <td> <p> CTL019 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Acute lymphoblastic leukemia </p> <p> &nbsp; </p> </td> <td> <p> II </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Novartis </p> <p> &nbsp; </p> </td> <td> <p> CTL019 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Diffuse large B-cell lymphoma </p> <p> &nbsp; </p> </td> <td> <p> II </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Novartis </p> <p> &nbsp; </p> </td> <td> <p> CTL019 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Multiple myeloma </p> <p> &nbsp; </p> </td> <td> <p> I </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Kite </p> <p> &nbsp; </p> </td> <td> <p> KTE-C19 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Chronic lymphocytic leukemia/small cell lymphocytic lymphoma </p> <p> &nbsp; </p> </td> <td> <p> I/II </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Kite </p> <p> &nbsp; </p> </td> <td> <p> KTE-C19 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Diffuse large B-cell lymphoma </p> <p> &nbsp; </p> </td> <td> <p> I/II </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Kite </p> <p> &nbsp; </p> </td> <td> <p> KTE-C19 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Indolent Non-Hodgkin's lymphoma </p> <p> &nbsp; </p> </td> <td> <p> I/II </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Kite </p> <p> &nbsp; </p> </td> <td> <p> KTE-C19 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Acute lymphoblastic leukemia </p> <p> &nbsp; </p> </td> <td> <p> I </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Kite </p> <p> &nbsp; </p> </td> <td> <p> KTE-C19 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Mantle cell lymphoma </p> <p> &nbsp; </p> </td> <td> <p> I </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Kite </p> <p> &nbsp; </p> </td> <td> <p> EGFRvIIICAR </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Brain cancer </p> <p> &nbsp; </p> </td> <td> <p> I/II </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Juno </p> <p> &nbsp; </p> </td> <td> <p> JCAR014 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Hematological Cancer </p> <p> &nbsp; </p> </td> <td> <p> I/II </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Juno </p> <p> &nbsp; </p> </td> <td> <p> JCAR015 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Acute lymphoblastic leukemia </p> <p> &nbsp; </p> </td> <td> <p> II </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Juno </p> <p> &nbsp; </p> </td> <td> <p> JCAR015 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Non-Hodgkin's lymphoma </p> <p> &nbsp; </p> </td> <td> <p> I </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Juno </p> <p> &nbsp; </p> </td> <td> <p> JCAR015 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Diffuse large B-cell lymphoma </p> <p> &nbsp; </p> </td> <td> <p> I </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Juno </p> <p> &nbsp; </p> </td> <td> <p> JCAR017 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Acute lymphoblastic leukemia </p> <p> &nbsp; </p> </td> <td> <p> I/II </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Juno </p> <p> &nbsp; </p> </td> <td> <p> JCAR017 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Non-Hodgkin's lymphoma </p> <p> &nbsp; </p> </td> <td> <p> I/II </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Juno </p> <p> &nbsp; </p> </td> <td> <p> JCAR018 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Acute lymphoblastic leukemia </p> <p> &nbsp; </p> </td> <td> <p> I </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Juno </p> <p> &nbsp; </p> </td> <td> <p> JCAR018 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Non-Hodgkin's lymphoma </p> <p> &nbsp; </p> </td> <td> <p> I </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Juno </p> <p> &nbsp; </p> </td> <td> <p> JCAR020 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Ovarian cancer </p> <p> &nbsp; </p> </td> <td> <p> I </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Juno </p> <p> &nbsp; </p> </td> <td> <p> JCAR021 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Non-Hodgkin's lymphoma </p> <p> &nbsp; </p> </td> <td> <p> I </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Juno </p> <p> &nbsp; </p> </td> <td> <p> JCAR023 </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Neuroendocrine tumors </p> <p> &nbsp; </p> </td> <td> <p> I </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Juno </p> <p> &nbsp; </p> </td> <td> <p> CD19 Armored CAR </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Hematologic cancers </p> <p> &nbsp; </p> </td> <td> <p> I </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Juno </p> <p> &nbsp; </p> </td> <td> <p> ROR-1 CAR-T </p> <p> &nbsp; </p> </td> <td> <p> Autologous </p> <p> &nbsp; </p> </td> <td> <p> Solid tumors </p> <p> &nbsp; </p> </td> <td> <p> Preclinical </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> National Institute of Health (NIH) </p> <p> &nbsp; </p> </td> <td> <p> Anti-mesothelin CAR </p> <p> &nbsp; </p> </td> <td> <p> Allogenic </p> <p> &nbsp; </p> </td> <td> <p> Solid tumors </p> <p> &nbsp; </p> </td> <td> <p> I/II </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> National Institute of Health (NIH) </p> <p> &nbsp; </p> </td> <td> <p> Anti-GD2 CAR </p> <p> &nbsp; </p> </td> <td> <p> Allogenic </p> <p> &nbsp; </p> </td> <td> <p> Solid tumors </p> <p> &nbsp; </p> </td> <td> <p> I </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Cellectis </p> <p> &nbsp; </p> </td> <td> <p> UCART123 </p> <p> &nbsp; </p> </td> <td> <p> Allogeneic </p> <p> &nbsp; </p> </td> <td> <p> Acute myelogenous leukemia </p> <p> &nbsp; </p> </td> <td> <p> Preclinical </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Cellectis </p> <p> &nbsp; </p> </td> <td> <p> UCART19 </p> <p> &nbsp; </p> </td> <td> <p> Allogeneic </p> <p> &nbsp; </p> </td> <td> <p> Acute lymphoblastic leukemia </p> <p> &nbsp; </p> </td> <td> <p> Preclinical </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Cellectis </p> <p> &nbsp; </p> </td> <td> <p> UCART22 </p> <p> &nbsp; </p> </td> <td> <p> Allogeneic </p> <p> &nbsp; </p> </td> <td> <p> Hematologic cancer </p> <p> &nbsp; </p> </td> <td> <p> Preclinical </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Cellectis </p> <p> &nbsp; </p> </td> <td> <p> UCART38 </p> <p> &nbsp; </p> </td> <td> <p> Allogeneic </p> <p> &nbsp; </p> </td> <td> <p> Acute lymphoblastic leukemia </p> <p> &nbsp; </p> </td> <td> <p> Preclinical </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Cellectis </p> <p> &nbsp; </p> </td> <td> <p> UCART38 </p> <p> &nbsp; </p> </td> <td> <p> Allogeneic </p> <p> &nbsp; </p> </td> <td> <p> Multiple myeloma </p> <p> &nbsp; </p> </td> <td> <p> Preclinical </p> <p> &nbsp; </p> </td> </tr> <tr> <td> <p> Cellectis </p> <p> &nbsp; </p> </td> <td> <p> UCARTCS1 </p> <p> &nbsp; </p> </td> <td> <p> Allogeneic </p> <p> &nbsp; </p> </td> <td> <p> Multiple myeloma </p> <p> &nbsp; </p> </td> <td> <p> Preclinical </p> <p> &nbsp; </p> </td> </tr> <tr> <td colspan="5"> <p> &nbsp; </p> </td> </tr> </table> <p> <p> Dustin Phan is an analyst with Datamonitor Healthcare. </p> 
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 310

<p> <b>An unexpected breakthrough announced by Cellectis for its experimental off-the-shelf CAR-T therapy has raised the possibility that much-hyped therapies using a patient's own cells, under development at Kite, Juno and Novartis, may become commercially obsolete before they even reach the market.</b> </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 68

Cellectis Success With OffTheShelf CART Threatens Kite Juno Novartis
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20151111T094446
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20151111T094446
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20151111T094446
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC030294
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 76

 Cellectis Success With Off-The-Shelf CAR-T Threatens Kite, Juno, Novartis  
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{23F0FDAE-F91C-4102-BBE8-1C9FEAD3C546}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

361423
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042522Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

7469b487-c6a2-4340-a24c-8532904d451d
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042522Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
